News summarySEC EDGARNov 9, 2026, 12:00 PM
ImmunityBio, 8-K (7.01, 9.01): Regulation FD disclosure
ImmunityBio said ANKTIVA plus BCG met the primary endpoint in its 370-patient QUILT-2.005 trial for BCG-naïve bladder cancer, with a statistically significant efficacy improvement versus BCG alone, and an FDA supplemental application remains on track by year-end 2026.